Retina

Improvements are seen after gene therapy for Leber congenital amaurosis.

According to a team of French investigators, every patient hospitalized with severe COVID-19 cases in their study had retinal and choroidal anomalies on indocyanine green angiography and optical coherence tomography images that were possibly related to the virus.

Bausch + Lomb and Clearside Biomedical announced Monday that the U.S. Food and Drug Administration has approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis.

Oxurion NV announced Wednesday the first patient to be dosed in the INTEGRAL phase 2 clinical study evaluating THR-687 as a treatment for patients with DME.

Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

David Boyer, MD, reports on the use of pegcetacoplan to treat geographic atrophy when administered monthly or every-other-month regimens in the phase 3 DERBY and OAKS studies.

Arshad Khanani, MD, MA, reports primary study findings from the phase 3 study on the Port Delivery System with ranibizumab.

Richard B. Rosen, MD, DSc(Hon), reports on the capabilities of using clinical OCT for imaging and measuring macular surface macrophage cells during the 2021 ASRS annual meeting.

Justis P. Ehlers, MD, speaks on the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.

Sunir Garg, MD, reports on the risk of presumed infectious endophthalmitis following administration of anti-VEFG injections in correlation with universal masking.

Yoshihiro Yonekawa, MD, reports on the findings of an investigation looking at the prevalence of endophthalmitis following minimally invasive glaucoma surgery.

Alcon's Paul Hallen offers a look at the highlights from the 2021 ASRS annual meeting's OIS panel as well as the company's latest innovations.

Rishi Singh, MD, reports on results from the VISTA and VIVID studies analyzing the use of intravitreal aflibercept injections to treat DME.

Caroline Baumal, MD, highlights results from the Phase 3 YOSEMITE and RHINE trials, providing an overview of the efficacy, safety and durability of faricimab in DME.

W. Lloyd Clark, MD, presents results of the nonproliferative diabetic retinopathy-focused PANORAMA study during the 2021 ASRS annual meeting.

Researchers consider frequency and factors in etiology of complication

Study: Older age and eyes with severe nonproliferative diabetic retinopathy or proliferative diabetic retinopathy had a higher risk of a vision loss event.

Graybug Vision reported Tuesday a full-data analysis from the phase 2b ALTISSIMO trial of GB-102 for the treatment of wet AMD.

American Society of Retinal Specialists program to drive awareness and action around retinal diseases that put millions at risk for blindness.

Orbis, with support from FedEx, is offering training that will develop ophthalmologists’ skills to treat diabetic retinopathy in China.

Future investigations will assess findings, evaluate their prognostic value.

Technology can track the progression of retinal abnormalities

The company will host Innovation Week from Sept. 21-23, demonstrating new data management innovations across devices, workflow solutions and software applications.

Pilot study shows promise of teaching surgeons with technology.

AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.

Marta Belmonte-Grau, MD discusses the potential risk for posterior capsular rupture during cataract surgery.

Tunde Peto, MD, offers advice on how to create the best virtual environment for patients diagnosed with diabetic eye disease.

Grazia Pertile, MD, discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.

Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.

Anat Loewenstein, MD, MHA, discusses how artificial intelligence can optimize optical coherence tomography.